Prodrugs. Do They Have Advantages in Clinical Practice?

Overview

Journal Drugs

Specialty Pharmacology

Date 1985 May 1

PMID 3891303

Citations 33

Authors

V J Stella

W N Charman

V H Naringrekar

Affiliations

Soon will be listed here.

Abstract

Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug. The scientific rationale, based on clinical, pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.

Citing Articles

Three-component modular synthesis of chiral 1,3-dioxoles a Rh-catalyzed carbenic olefination cascade.

Huang S, Luo J, Chen P, Chen J, Wang Z Chem Sci. 2024; .

PMID: 39444556 PMC: 11494413. DOI: 10.1039/d4sc06166g.

Synthesis of 1H-isoindolin-1-ones via a simple photodecarboxylative addition of carboxylates to phthalimides and evaluation of their antibiotic activity.

Kemp A, Durand M, Wall D, Szieber P, Hermanns M, Oelgemoller M Photochem Photobiol Sci. 2024; 23(7):1353-1360.

PMID: 38888704 DOI: 10.1007/s43630-024-00600-y.

MRGPRX4 mediates phospho-drug-associated pruritus in a humanized mouse model.

Chien D, Limjunyawong N, Cao C, Meixiong J, Peng Q, Ho C Sci Transl Med. 2024; 16(746):eadk8198.

PMID: 38718132 PMC: 11645656. DOI: 10.1126/scitranslmed.adk8198.

Development and Evaluation of EDTA-Treated Rabbits for Bioavailability Study of Chelating Drugs Using Levofloxacin, Ciprofloxacin, Hemiacetal Ester Prodrugs, and Tetracycline.

Maeda Y, Teraoka H, Okada A, Yamamoto M, Natsuyama S, Hieda Y Pharmaceutics. 2023; 15(6).

PMID: 37376038 PMC: 10301896. DOI: 10.3390/pharmaceutics15061589.

Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group.

Bauer A, Berben P, Chakravarthi S, Chattorraj S, Garg A, Gourdon B Pharm Res. 2023; 40(7):1601-1631.

PMID: 36811809 DOI: 10.1007/s11095-022-03391-y.

References

Mandell A, Stentz F, Kitabchi A . Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology. 1978; 85(3):268-75. DOI: 10.1016/s0161-6420(78)35668-2. View

Yale H . The long-acting neuroleptics: a retrospective appraisal. Drug Metab Rev. 1978; 8(2):251-62. DOI: 10.3109/03602537808993787. View

Theeuwes F . Elementary osmotic pump. J Pharm Sci. 1975; 64(12):1987-91. DOI: 10.1002/jps.2600641218. View

Sinkula A, MOROZOWICH W, ROWE E . Chemical modification of clindamycin: synthesis and evaluation of selected esters. J Pharm Sci. 1973; 62(7):1106-11. DOI: 10.1002/jps.2600620711. View

STEWART G . Macromolecular residues contributing to the allergenicity of penicillins and cephalosporins. Antimicrob Agents Chemother (Bethesda). 1967; 7:543-9. DOI: 10.1128/AAC.7.5.543. View

Andersgaard H, FINHOLT P, Gjermundsen R, Hoyland T . Rate studies on dissolution and enzymatic hydrolysis of chloramphenicol palmitate. Acta Pharm Suec. 1974; 11(3):239-48. View

Gregoriadis G . Targeting of drugs. Nature. 1977; 265(5593):407-11. DOI: 10.1038/265407a0. View

Stella V, Himmelstein K . Prodrugs and site-specific drug delivery. J Med Chem. 1980; 23(12):1275-82. DOI: 10.1021/jm00186a001. View

Kupchan S, Casy A, SWINTOSKY J . Drug latentiation. Synthesis and preliminary evaluation of testosterone derivatives. J Pharm Sci. 1965; 54(4):514-24. DOI: 10.1002/jps.2600540404. View

10.

EDMONDSON H . Parenteral and oral clindamycin therapy in surgical infections: a preliminary report. Ann Surg. 1973; 178(5):637-42. PMC: 1355746. DOI: 10.1097/00000658-197311000-00014. View

11.

DeHaan R, Metzler C, Schellenberg D, Vandenbosch W . Pharmacokinetic studies of clindamycin phosphate. J Clin Pharmacol. 1973; 13(5):190-209. DOI: 10.1002/j.1552-4604.1973.tb00208.x. View

12.

Redwood D . Conservative treatment of chronic heart block. Br Med J. 1969; 1(5635):26-9. PMC: 1981820. DOI: 10.1136/bmj.1.5635.26. View

13.

Gruber Jr C, STEPHENS V, TERRILL P . Propoxyphene napsylate: chemistry and experimental design. Toxicol Appl Pharmacol. 1971; 19(3):423-6. DOI: 10.1016/0041-008x(71)90001-9. View

14.

DUGGAN D, Hare L, Ditzler C, LEI B, Kwan K . The disposition of sulindac. Clin Pharmacol Ther. 1977; 21(3):326-35. DOI: 10.1002/cpt1977213326. View

15.

Shek E, Higuchi T, Bodor N . Improved delivery through biological membranes. 3. Delivery of N-methylpyridinium-2-carbaldoxime chloride through the blood-brain barrier in its dihydropyridine pro-drug form. J Med Chem. 1976; 19(1):113-7. DOI: 10.1021/jm00223a019. View

16.

CLARK Jr R, VARNER E . New esters of erythromycin. Antibiot Chemother (Northfield). 2014; 7(9):487-9. View

17.

Davies G, Driver G, HOGGARTH E, Martin A, PAIGE M, ROSE F . Studies in the chemotherapy of tuberculosis: ethyl mercaptan and related compounds. Br J Pharmacol Chemother. 1956; 11(4):351-6. PMC: 1510553. DOI: 10.1111/j.1476-5381.1956.tb00001.x. View

18.

GRAY L, CONGER A, Ebert M, HORNSEY S, Scott O . The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953; 26(312):638-48. DOI: 10.1259/0007-1285-26-312-638. View

19.

Sjovall J, Magni L, Bergan T . Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin. Antimicrob Agents Chemother. 1978; 13(1):90-6. PMC: 352190. DOI: 10.1128/AAC.13.1.90. View

20.

ARIENS E . Molecular pharmacology, a basis for drug design. Fortschr Arzneimittelforsch. 1966; 10:429-529. DOI: 10.1007/978-3-0348-7059-7_8. View